CCR S.A. (“Company”) (B3: CCRO3; Bloomberg: CCRO3BZ; Reuters: CCRO3.SA), in response to the questions sent by B3 via Official Letter, as shown in the transcript below, hereby opportunely clarifies the following:

“[…] Considering the end of the period, on February 21, 2020, for shareholders to dissent from the amendment to the Bylaws, approved at the ESM of January 10, 2020, we request that you provide us with clarifications, until March 4, 2020, on whether this Company will reconsider or ratify the abovementioned amendment, in accordance with Art. 137, paragraph 3, of Law 6,404/76..xx

We also request that you provide us with clarifications on the payment date of the amount of the reimbursement to dissident shareholders, if any. […]”

In response to the Official Letter, the Company clarifies that, once the period to exercise the right to withdraw has ended, we verified that only two shareholders exercised their right, who hold, together, 2,000 shares issued by the Company, without requesting the preparation of a special balance sheet.

As a result, the Company informs that it will not invoke Art. 137, paragraph 3, of Law 6,404/76, being the amendment to the Bylaws ratified, under the terms approved at the Extraordinary Shareholders’ Meeting held on January 10, 2020.

The Company will pay the amount of the reimbursement to the shareholders who exercised their right to withdraw on March 23, 2020.

Finally, the Company is available for any further clarification.



Chief Financial and Investor Relations Officer